title: Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort.
abstract: BACKGROUND
  Osteogenesis imperfecta (OI) is a heritable disorder of variable phenotype that is characterised by bone fragility and frequent fractures, with deformities and short stature in more severe cases.
  
  
  OBJECTIVE
  We sought to review the response to treatment in a cohort of adult patients with OI.
  
  
  METHODS
  Charts of 16 patients with OI attending a metabolic bone disease clinic were reviewed, particularly with respect to the response to treatment using bisphosphonates and recombinant human parathyroid hormone (rhPTH). The response to treatment was assessed by monitoring bone mineral density (BMD) and bone turnover markers (BTMs).
  
  
  RESULTS
  In response to bisphosphonate therapy, median (range) BMD increased at the spine by 15.1(6.9-43.7) %. In response to rhPTH in 2 cases, spinal BMD increased by 40.3 and 27.2 %.
  
  
  CONCLUSIONS
  OI is debilitating disorder, but the course of the disease may be altered by treatment that increases BMD such as bisphosphonates and rhPTH. Both serial BMD and BTM aid in assessing response to intervention. Further study is needed with regard to fracture prevention.
authors.affiliation: Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland, esther.osullivan2@hse.ie.
authors.forename: E S
authors.initials: ES
authors.lastname: O'Sullivan
authors.forename: S
authors.initials: S
authors.lastname: van der Kamp
authors.forename: M
authors.initials: M
authors.lastname: Kilbane
authors.forename: M
authors.initials: M
authors.lastname: McKenna
mesh_terms: D000293:Adolescent; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D007494:Ireland; D008297:Male; D008875:Middle Aged; D010013:Osteogenesis Imperfecta / Q000188:drug therapy* / Q000235:genetics; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010384:Pelvic Bones / Q000187:drug effects / Q000502:physiology; D010641:Phenotype; D011994:Recombinant Proteins / Q000627:therapeutic use; D013131:Spine / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C470125:PTH protein, human; D010281:Parathyroid Hormone; D011994:Recombinant Proteins
references.citation: Bone. 2007 Apr;40(4):821-7
references.pmid: 17223617
references.citation: Nat Rev Endocrinol. 2011 Jun 14;7(9):540-57
references.pmid: 21670757
references.citation: N Engl J Med. 2001 May 10;344(19):1434-41
references.pmid: 11346808
references.citation: Am J Hum Genet. 2012 Aug 10;91(2):349-57
references.pmid: 22863195
references.citation: J Bone Miner Res. 2010 Jan;25(1):32-40
references.pmid: 19580461
references.citation: J Bone Miner Res. 2009 Jul;24(7):1282-9
references.pmid: 19257821
references.citation: Skeletal Radiol. 1987;16(5):360-3
references.pmid: 3629280
references.citation: Ir Med J. 2008 Apr;101(4):101-2
references.pmid: 18557509
references.citation: J Clin Endocrinol Metab. 2011 Feb;96(2):355-64
references.pmid: 21106710
references.citation: J Bone Miner Res. 2004 Nov;19(11):1779-86
references.pmid: 15476577
references.citation: Am J Hum Genet. 2012 Aug 10;91(2):343-8
references.pmid: 22863190
references.citation: J Bone Miner Res. 2006 Mar;21(3):374-9
references.pmid: 16491284
references.citation: Am J Med. 2008 Jun;121(6):475-483.e3
references.pmid: 18501224
references.citation: Lancet. 2004 Apr 24;363(9418):1377-85
references.pmid: 15110498
references.citation: J Med Genet. 1979 Apr;16(2):101-16
references.pmid: 458828
references.citation: J Bone Miner Res. 2003 Jan;18(1):126-30
references.pmid: 12510813
references.citation: Am J Med Genet A. 2011 May;155A(5):943-68
references.pmid: 21438135
references.citation: Osteoporos Int. 2012 Jan;23(1):285-94
references.pmid: 21739105
references.citation: J Bone Miner Res. 2012 Dec;27(12):2429-37
references.pmid: 22991313
references.citation: J Bone Miner Res. 2010 Nov;25(11):2267-94
references.pmid: 20842676
references.citation: Eur J Med Genet. 2010 Jan-Feb;53(1):1-5
references.pmid: 19878741
references.citation: J Bone Miner Metab. 2012 Jul;30(4):434-8
references.pmid: 22065238
references.citation: J Bone Miner Res. 2006 Feb;21(2):300-6
references.pmid: 16418786
references.citation: Hum Mutat. 2008 Dec;29(12):1435-42
references.pmid: 18566967